Developer docs
API playgroundTry for free, no card

Search company profiles

Breathonix

Full company profile

uuid00045ho

Namestring
Breathonix
Legal namestring
Breathonix Pte Ltd.
Websiteurl
breathonix.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Breathonix is a Singapore-based deep-tech company founded in 2018 as a spin-off from the National University of Singapore (NUS) through the Graduate Research Innovation Programme (GRIP). The company specializes in breath-based disease detection using Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with proprietary machine learning algorithms to analyze volatile organic compound (VOC) signatures in exhaled breath. Its core products include the BreFence Go COVID-19 Breath Test System, which received Health Sciences Authority (HSA) provisional authorization, and the MetaDR Breath Analyser for diabetes monitoring. The company is also developing applications for lung cancer detection.

The business operates on a B2B model, selling or deploying its breath analysis hardware and consumables to enterprise and government clients. Notable commercial agreements include a USD 20 million deal with Vingroup for 30 machines in Vietnam and an exclusive distribution partnership with MyEG in Malaysia. The company has secured multiple regulatory clearances including HSA, CE Mark, MDA, and FDA registration, along with ISO 13485 certification, enabling cross-border deployment. Revenue mechanics appear to be a combination of equipment sales and ongoing service/consumable contracts, though no recurring revenue figures are disclosed.

Customer concentration is significant, with major contracts tied to government health authorities (Singapore MOH, UAE DHA/MBRU) and large enterprise partners (Vingroup, MyEG). The company maintains a modest headcount of 11-50 employees and has raised approximately USD 300K-400K in total funding through pre-seed grants and a Pre-Series A round targeting USD 5 million. Its competitive position rests on 6 patents, peer-reviewed clinical validation, and an experienced founding team led by Prof T Venkatesan (h-index 110, 6 prior startups).

Short descriptiontext

Breathonix is a Singapore-based NUS spin-off that develops PTR-MS breath analysis systems with proprietary machine learning algorithms for non-invasive disease detection, including COVID-19, diabetes, and lung cancer, serving enterprise and government healthcare clients across Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath diagnostics, disease detection, mass spectrometry, COVID-19 testing, medical devices
Industry1 code
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Medical Diagnostics Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Breath Test Hardware and Service Provision
TypeHardware Sales
Description

One-stop service model providing both proprietary breath test machines and professional on-site manpower. Target pricing of US$20 per test, significantly lower than PCR tests costing ~$200.

breathonix.com
2COVID-19 Breath Testing System
TypeHardware Sales
Description

Sale of BreFence Go COVID-19 breath test systems with disposable mouthpieces to governments, hospitals, airports, and enterprises for mass screening deployments.

breathonix.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Per-test pricing model
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Target pricing of US$20 per test when testing approximately 5,000 people per month per machine. This represents >70% cost reduction compared to RT-PCR tests estimated at $200 per test. Pricing depends on volume and number of tests conducted.

breathonix.com
2One-stop service model
ModelOtherBilling cadenceMulti-year contract
Notes

Full service provision including professional manpower and machines on-site at customer premises. Service includes continuous system upgrading of screening accuracy.

breathonix.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BreFence Go
Description

COVID-19 Breath Test System - real-time, non-invasive breath test for qualitative detection of volatile organic compounds (VOCs) indicative of COVID-19 presence.

breathonix.com
+1 more record
Core offering1 text field

Breathonix develops proprietary breath analysis systems that use Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with machine learning algorithms to detect Volatile Organic Compounds (VOCs) in exhaled breath. The company manufactures and sells two core products: the BreFence Go COVID-19 Breath Test System for rapid infectious disease screening and the MetaDR Breath Analyser for non-invasive ketone monitoring in diabetes and diabetic ketoacidosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Results delivered in under 60 seconds from breath sampling
+4 more records
Product overview1 text field

Breathonix is a deep-tech venture specializing in advanced breath analysis technology for early disease detection. The company offers two core breath analysis products: (1) the BreFence Go COVID-19 Breath Test System, a mass spectrometry-based diagnostic platform that detects VOCs in exhaled breath for COVID-19 screening and received HSA provisional authorization in Singapore, and (2) the MetaDR Breath Analyser, an FDA-registered portable handheld device for breath ketone monitoring for diabetes management and diabetic ketoacidosis detection. Both products use proprietary breath sampling technology and AI-based algorithms to analyze volatile organic compounds, representing a unified platform approach to non-invasive disease detection through breath biomarkers.

Product and service2 records
1BreFence Go COVID-19 Breath Test System
CategoryInfectious Disease Diagnostic Device
Description

A real-time, non-invasive breath test system for qualitative detection of volatile organic compounds (VOCs) in human breath, used by governments, hospitals, airports and large enterprises for mass COVID-19 screening. Uses mass spectrometry combined with machine learning algorithms to generate results in under 60 seconds with 85.7% sensitivity and 97% specificity.

2MetaDR Breath Analyser
CategoryMetabolic Monitoring Device
Description

A portable hand-held FDA-registered breath analyser for rapid, safe and non-invasive breath ketone monitoring, used for home monitoring of diabetes, emergency diagnosis of diabetic ketoacidosis, and non-invasive monitoring of epilepsy. Delivers results in 10 seconds and pairs with a companion phone app for data storage and health management.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2024-01-11
Description

Collaborative study published in Open Access Government focused on non-invasive VOC breathomics for pandemic preparedness. Supported by NSF funding, combining OU's clinical research and AI/ML expertise with Breathonix's breath analysis technology.

Strategic tierStrategicTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-12-09
Description

Strategic technology partnership for digital innovation and data-driven deployment efforts. Zühlke provided solution architecture support and identified opportunities for scaling digital and innovation capabilities, including data security considerations.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-07-16
Description

Integration of BreFence Go breath test with Accredify's digital verifiable COVID-19 test result issuance system. Results will be internationally recognized in 82 countries and 292 airlines, compliant with Singapore's HealthCerts schema.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-04
Description

Vietnamese conglomerate deal valued at over 460 billion VND (20 million USD) comprising 30 testing machines and disposable mouthpieces capable of collecting 2 million samples. System presented to Vietnam Ministry of Health.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-05-27
Description

Malaysia-based government services provider appointed as exclusive distribution partner for commercial sale, marketing, and deployment of Breathonix COVID-19 breath testing systems in Malaysia. MyEG to apply for regulatory approvals and certifications for commercial availability.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-13
Description

Joint clinical trial at DHA's Nadd Al Hamar primary health care centre for 2,500 patients to assess accuracy of rapid COVID-19 breath test. Trial part of UAE's efforts to foster medical research and innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-13
Description

Joint clinical trial collaboration for rapid COVID-19 breath test accuracy assessment. MBRU served as catalyst for medical research in the region with focus on COVID-19 studies and technology transfer.

Strategic tierMinorTypeOthersAnnounced on2021-03-13
Description

Emirates provided world-class services and sponsored expedited transportation of Breathonix's breath test system from Singapore to Dubai to support clinical trial. Part of Dubai's efforts to implement innovative testing approaches.

Strategic tierFoundationalTypeOthers
Description

Spin-off company from NUS through Graduate Research Innovation Programme (GRIP). Technology originated from 6+ years of research at NUS Nanoscience and Nanotechnology Institute. Supported by NUS in regulatory approvals and clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Working with MOH for deployment trial at land checkpoint (Tuas Checkpoint) where incoming travelers undergo screening with BreFence Go COVID-19 breath test alongside antigen rapid tests.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

MGC Diagnostics is an established provider of pulmonary function testing equipment and related software. It is comparable to Breathonix in the pulmonary function testing (PFT) category, although focused on traditional lab-based PFT hardware rather than mass-spectrometry VOC detection.

TypeDirect peer
Description

Spirosure (formerly Advanced Breath Diagnostics) develops breath-based diagnostic devices, particularly for respiratory conditions such as asthma. It overlaps with Breathonix in deploying non-invasive breath analysis hardware for clinical screening.

3CMI Health
TypeEmerging player
Description

CMI Health manufactures handheld respiratory monitoring devices, including breath-based analyzers. It is comparable to Breathonix's MetaDR product line in portable breath analysis, though with a broader consumer/wellness positioning.

TypeBroad incumbent
Description

Vyaire Medical is a large respiratory diagnostics company supplying pulmonary function testing and spirometry equipment globally. It competes with Breathonix's breath-based diagnostic equipment in hospital and clinical lab settings, though with broader product lines.

TypeDirect peer
Description

Menssana Research develops breath tests for a range of diseases using mass-spectrometry-based VOC detection. It is directly comparable to Breathonix in terms of technology platform and target applications (infectious disease, oncology, metabolic monitoring).

TypeBroad incumbent
Description

Pulmonx is a publicly traded lung diagnostics and interventional pulmonology company. While more procedurally focused, it addresses the same end customer (pulmonologists, lung cancer programs) and competes for budget allocation in the respiratory diagnostic pathway.

7AerNos
TypeEmerging player
Description

AerNos builds nano-sensor-based breath analysis devices for health and environmental monitoring. While more sensor-focused than Breathonix's mass spectrometry approach, it competes in the same breath-based diagnostic category, particularly for point-of-care and consumer health use cases.

TypeBroad incumbent
Description

Cepheid's GeneXpert PCR systems are the dominant rapid molecular diagnostic platform that Breathonix positions BreFence Go against. While not a breath company, it is the incumbent standard Breathonix's cost/speed proposition targets in the COVID-19 and infectious disease screening market.

TypeEmerging player
Description

Resmon offers AI-based lung function/respiratory analysis using cough and breath acoustics. It represents an emerging digital-health approach that could partially substitute for or complement Breathonix's hardware-based breath diagnostic pathway in screening settings.

TypeDirect peer
Description

Owlstone Medical is a UK-based breath biopsy company that uses VOC analysis for early disease detection, including lung cancer. It is the closest direct peer to Breathonix, operating in the same breath-based diagnostic category with overlapping disease indications and a similar platform-based, biomarker-driven approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breathonix

Medical Diagnostics Devicesbreathonix.com

Breathonix is a Singapore-based NUS spin-off that develops PTR-MS breath analysis systems with proprietary machine learning algorithms for non-invasive disease detection, including COVID-19, diabetes, and lung cancer, serving enterprise and government healthcare clients across Asia.

What Breathonix does

Breathonix is a Singapore-based deep-tech company founded in 2018 as a spin-off from the National University of Singapore (NUS) through the Graduate Research Innovation Programme (GRIP). The company specializes in breath-based disease detection using Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with proprietary machine learning algorithms to analyze volatile organic compound (VOC) signatures in exhaled breath. Its core products include the BreFence Go COVID-19 Breath Test System, which received Health Sciences Authority (HSA) provisional authorization, and the MetaDR Breath Analyser for diabetes monitoring. The company is also developing applications for lung cancer detection.

The business operates on a B2B model, selling or deploying its breath analysis hardware and consumables to enterprise and government clients. Notable commercial agreements include a USD 20 million deal with Vingroup for 30 machines in Vietnam and an exclusive distribution partnership with MyEG in Malaysia. The company has secured multiple regulatory clearances including HSA, CE Mark, MDA, and FDA registration, along with ISO 13485 certification, enabling cross-border deployment. Revenue mechanics appear to be a combination of equipment sales and ongoing service/consumable contracts, though no recurring revenue figures are disclosed.

Customer concentration is significant, with major contracts tied to government health authorities (Singapore MOH, UAE DHA/MBRU) and large enterprise partners (Vingroup, MyEG). The company maintains a modest headcount of 11-50 employees and has raised approximately USD 300K-400K in total funding through pre-seed grants and a Pre-Series A round targeting USD 5 million. Its competitive position rests on 6 patents, peer-reviewed clinical validation, and an experienced founding team led by Prof T Venkatesan (h-index 110, 6 prior startups).

Breathonix firmographics

Firmographics
Name
Breathonix
Legal name
Breathonix Pte Ltd.
Website
https://breathonix.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Breathonix is a Singapore-based NUS spin-off that develops PTR-MS breath analysis systems with proprietary machine learning algorithms for non-invasive disease detection, including COVID-19, diabetes, and lung cancer, serving enterprise and government healthcare clients across Asia.
Ownership category
akta.pro rank

Breathonix industry classification

Industry
Product category
Medical Diagnostics Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Breath diagnostics
  • Disease detection
  • Mass spectrometry
  • COVID-19 testing
  • Medical devices

Where Breathonix is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

Breathonix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Breath Test Hardware and Service Provision: One-stop service model providing both proprietary breath test machines and professional on-site manpower. Target pricing of US$20 per test, significantly lower than PCR tests costing ~$200.
  2. COVID-19 Breath Testing System: Sale of BreFence Go COVID-19 breath test systems with disposable mouthpieces to governments, hospitals, airports, and enterprises for mass screening deployments.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPer-test pricing model
OtherMulti-year contractOne-stop service model

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Breathonix product offering

Product offering

Core offering

Breathonix develops proprietary breath analysis systems that use Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with machine learning algorithms to detect Volatile Organic Compounds (VOCs) in exhaled breath. The company manufactures and sells two core products: the BreFence Go COVID-19 Breath Test System for rapid infectious disease screening and the MetaDR Breath Analyser for non-invasive ketone monitoring in diabetes and diabetic ketoacidosis.

Product overview

Breathonix is a deep-tech venture specializing in advanced breath analysis technology for early disease detection. The company offers two core breath analysis products: (1) the BreFence Go COVID-19 Breath Test System, a mass spectrometry-based diagnostic platform that detects VOCs in exhaled breath for COVID-19 screening and received HSA provisional authorization in Singapore, and (2) the MetaDR Breath Analyser, an FDA-registered portable handheld device for breath ketone monitoring for diabetes management and diabetic ketoacidosis detection. Both products use proprietary breath sampling technology and AI-based algorithms to analyze volatile organic compounds, representing a unified platform approach to non-invasive disease detection through breath biomarkers.

Differentiator

Problem solved

Functional benefit

Brands

  • BreFence Go: COVID-19 Breath Test System - real-time, non-invasive breath test for qualitative detection of volatile organic compounds (VOCs) indicative of COVID-19 presence.
  • MetaDR

Products and services

  • BreFence Go COVID-19 Breath Test System A real-time, non-invasive breath test system for qualitative detection of volatile organic compounds (VOCs) in human breath, used by governments, hospitals, airports and large enterprises for mass COVID-19 screening. Uses mass spectrometry combined with machine learning algorithms to generate results in under 60 seconds with 85.7% sensitivity and 97% specificity.
  • MetaDR Breath Analyser A portable hand-held FDA-registered breath analyser for rapid, safe and non-invasive breath ketone monitoring, used for home monitoring of diabetes, emergency diagnosis of diabetic ketoacidosis, and non-invasive monitoring of epilepsy. Delivers results in 10 seconds and pairs with a companion phone app for data storage and health management.

Quantifiable outcome

  • Results delivered in under 60 seconds from breath sampling
  • +4 more outcomes

Companies that use Breathonix

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Breathonix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature5 records

Breathonix partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic, core, minor and foundational.

  • University of OklahomastrategicStrategic or Co-development Partner · 11 January 2024Collaborative study published in Open Access Government focused on non-invasive VOC breathomics for pandemic preparedness. Supported by NSF funding, combining OU's clinical research and AI/ML expertise with Breathonix's breath analysis technology.
  • ZühlkestrategicImplementation/ SI/ Consulting Partner · 9 December 2021Strategic technology partnership for digital innovation and data-driven deployment efforts. Zühlke provided solution architecture support and identified opportunities for scaling digital and innovation capabilities, including data security considerations.
  • AccredifycoreTechnology or Integration · 16 July 2021Integration of BreFence Go breath test with Accredify's digital verifiable COVID-19 test result issuance system. Results will be internationally recognized in 82 countries and 292 airlines, compliant with Singapore's HealthCerts schema.
  • VingroupcoreChannel Partner/ Reseller/ Distributor · 4 June 2021Vietnamese conglomerate deal valued at over 460 billion VND (20 million USD) comprising 30 testing machines and disposable mouthpieces capable of collecting 2 million samples. System presented to Vietnam Ministry of Health.
  • MyEG ServicescoreChannel Partner/ Reseller/ Distributor · 27 May 2021Malaysia-based government services provider appointed as exclusive distribution partner for commercial sale, marketing, and deployment of Breathonix COVID-19 breath testing systems in Malaysia. MyEG to apply for regulatory approvals and certifications for commercial availability.
  • Dubai Health Authority (DHA)coreStrategic or Co-development Partner · 13 March 2021Joint clinical trial at DHA's Nadd Al Hamar primary health care centre for 2,500 patients to assess accuracy of rapid COVID-19 breath test. Trial part of UAE's efforts to foster medical research and innovation.
  • Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU)coreStrategic or Co-development Partner · 13 March 2021Joint clinical trial collaboration for rapid COVID-19 breath test accuracy assessment. MBRU served as catalyst for medical research in the region with focus on COVID-19 studies and technology transfer.
  • Emirates AirlineminorOthers · 13 March 2021Emirates provided world-class services and sponsored expedited transportation of Breathonix's breath test system from Singapore to Dubai to support clinical trial. Part of Dubai's efforts to implement innovative testing approaches.
  • National University of Singapore (NUS)foundationalOthersSpin-off company from NUS through Graduate Research Innovation Programme (GRIP). Technology originated from 6+ years of research at NUS Nanoscience and Nanotechnology Institute. Supported by NUS in regulatory approvals and clinical trials.
  • Singapore Ministry of HealthcoreStrategic or Co-development PartnerWorking with MOH for deployment trial at land checkpoint (Tuas Checkpoint) where incoming travelers undergo screening with BreFence Go COVID-19 breath test alongside antigen rapid tests.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Breathonix competitors and assessment

Company assessment

Broad incumbents

  • MGC Diagnostics (now part of CAIRE): MGC Diagnostics is an established provider of pulmonary function testing equipment and related software. It is comparable to Breathonix in the pulmonary function testing (PFT) category, although focused on traditional lab-based PFT hardware rather than mass-spectrometry VOC detection.
  • Vyaire Medical: Vyaire Medical is a large respiratory diagnostics company supplying pulmonary function testing and spirometry equipment globally. It competes with Breathonix's breath-based diagnostic equipment in hospital and clinical lab settings, though with broader product lines.
  • Pulmonx: Pulmonx is a publicly traded lung diagnostics and interventional pulmonology company. While more procedurally focused, it addresses the same end customer (pulmonologists, lung cancer programs) and competes for budget allocation in the respiratory diagnostic pathway.
  • Cepheid (a Danaher company): Cepheid's GeneXpert PCR systems are the dominant rapid molecular diagnostic platform that Breathonix positions BreFence Go against. While not a breath company, it is the incumbent standard Breathonix's cost/speed proposition targets in the COVID-19 and infectious disease screening market.

Direct peers

  • Spirosure: Spirosure (formerly Advanced Breath Diagnostics) develops breath-based diagnostic devices, particularly for respiratory conditions such as asthma. It overlaps with Breathonix in deploying non-invasive breath analysis hardware for clinical screening.
  • Menssana Research: Menssana Research develops breath tests for a range of diseases using mass-spectrometry-based VOC detection. It is directly comparable to Breathonix in terms of technology platform and target applications (infectious disease, oncology, metabolic monitoring).
  • Owlstone Medical: Owlstone Medical is a UK-based breath biopsy company that uses VOC analysis for early disease detection, including lung cancer. It is the closest direct peer to Breathonix, operating in the same breath-based diagnostic category with overlapping disease indications and a similar platform-based, biomarker-driven approach.

Emerging players

  • CMI Health: CMI Health manufactures handheld respiratory monitoring devices, including breath-based analyzers. It is comparable to Breathonix's MetaDR product line in portable breath analysis, though with a broader consumer/wellness positioning.
  • AerNos: AerNos builds nano-sensor-based breath analysis devices for health and environmental monitoring. While more sensor-focused than Breathonix's mass spectrometry approach, it competes in the same breath-based diagnostic category, particularly for point-of-care and consumer health use cases.
  • Resmon (used to be: Resmed SaaS / Resmon Med): Resmon offers AI-based lung function/respiratory analysis using cough and breath acoustics. It represents an emerging digital-health approach that could partially substitute for or complement Breathonix's hardware-based breath diagnostic pathway in screening settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Breathonix social profiles

Digital presence

Breathonix compliance and trust

Trust signal

Compliance5 records

Breathonix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breathonix leadership team

Management profile

Number of profiles

Profiles8 records

Breathonix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breathonix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breathonix

What does Breathonix do?

Breathonix develops proprietary breath analysis systems that use Proton Transfer Reaction Mass Spectrometry (PTR-MS) combined with machine learning algorithms to detect Volatile Organic Compounds (VOCs) in exhaled breath. The company manufactures and sells two core products: the BreFence Go COVID-19 Breath Test System for rapid infectious disease screening and the MetaDR Breath Analyser for non-invasive ketone monitoring in diabetes and diabetic ketoacidosis.

Is Breathonix a public or private company?

Breathonix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Breathonix founded?

Breathonix was founded in 2018. It employs 1 to 10 people.

Where is Breathonix based?

Breathonix is headquartered in Singapore, Singapore, in the Asia region.

How does Breathonix make money?

Two revenue lines are on record. Breath Test Hardware and Service Provision is the primary driver. The others are COVID-19 Breath Testing System.

Who are Breathonix's main competitors?

Broad incumbents on record are MGC Diagnostics (now part of CAIRE), Vyaire Medical, Pulmonx and Cepheid (a Danaher company). Direct peers are Spirosure, Menssana Research and Owlstone Medical. Emerging players are CMI Health, AerNos and Resmon (used to be: Resmed SaaS / Resmon Med).

Does Breathonix have an API?

No public API is recorded for Breathonix.

What industry is Breathonix in?

Breathonix's product category is Medical Diagnostics Devices. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Open Access GovernmentRevolutionising disease detection: The emergence of non-invasive VOC breathomicsResearchers from the University of Oklahoma, supported by National Science Foundation funding, are developing a non-invasive diagnostic technology called Breathomics that detects diseases through volatile organic compounds in exhaled breath. The project aims to create rapid, point-of-care tests with over 90% sensitivity and specificity for conditions such as cancer and respiratory viruses. While primarily an academic initiative, the article highlights commercial entity Breathonix as a key player in the evolving landscape of breath analysis technology.AxiosSingapore approves COVID breath test that gives results within minuteSingapore health regulators provisionally authorized a COVID-19 breath test from NUS startup Breathonix, which returns results within a minute. The test achieved 93% sensitivity and 95% specificity in a pilot study of 180 patients. Manufacturers are now working with the Ministry of Health on a deployment trial at a land checkpoint.PR NewswireBreathonix announces 60 secs, on-site, non-intrusive rapid breath test for COVID-19Breathonix, a deep-tech startup from the National University of Singapore, has developed a rapid breath test for COVID-19 that delivers results in 60 seconds on-site with 93% sensitivity and 95% specificity, based on a pilot clinical trial involving 180 patients at the National Centre for Infectious Diseases. The test uses mass spectrometry to detect Volatile Organic Compounds in breath and is non-invasive, requiring only exhalation into a disposable mouthpiece. The company plans to deploy pilots in Singapore within weeks and internationally pending regulatory approval, targeting $20 per test—over 70% cheaper than standard PCR tests—with potential deployment at airports, ports, sports venues, and events.